ParkinsonCanadaV1, Main, Exploration, bibRecord, 001646

Involvement of the Fcγ Receptor in a Chronic N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss*

Identifieur interne : 001646 ( Main/Exploration ); précédent : 001645; suivant : 001647

Involvement of the Fcγ Receptor in a Chronic N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss*

Auteurs : Arman Lira ; Jerzy Kulczycki ; Ruth Slack ; Hymie Anisman ; David S. Park

Source :

The Journal of Biological Chemistry [ 0021-9258 ] ; 2011.

RBID : PMC:3190686

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology), Animals, Cell Death (drug effects), Cell Death (genetics), Cell Death (immunology), DNA-Binding Proteins (genetics), DNA-Binding Proteins (immunology), DNA-Binding Proteins (metabolism), Disease Models, Animal, Immunoglobulin G (genetics), Immunoglobulin G (immunology), Immunoglobulin G (metabolism), MPTP Poisoning (genetics), MPTP Poisoning (immunology), MPTP Poisoning (metabolism), Mice, Mice, Knockout, Neurotoxins (adverse effects), Neurotoxins (pharmacology), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (genetics), Parkinson Disease, Secondary (immunology), Receptors, IgG (genetics), Receptors, IgG (immunology), Receptors, IgG (metabolism).
MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurotoxins.
- chemical , genetics : DNA-Binding Proteins, Immunoglobulin G, Receptors, IgG.
- chemical , immunology : DNA-Binding Proteins, Immunoglobulin G, Receptors, IgG.
- chemical , metabolism : DNA-Binding Proteins, Immunoglobulin G, Receptors, IgG.
- chemical , pharmacology : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurotoxins.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Cell Death.
- genetics : Cell Death, MPTP Poisoning, Parkinson Disease, Secondary.
- immunology : Cell Death, MPTP Poisoning, Parkinson Disease, Secondary.
- metabolism : MPTP Poisoning.
- Animals, Disease Models, Animal, Mice, Mice, Knockout.

Abstract

Although there is growing evidence for a role of the innate immune response in Parkinson's disease, the nature of any humoral response in dopaminergic degeneration is uncertain. Here we report on a protracted N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of dopaminergic death that potentially allows a more full adaptive humoral response to develop. Rag2 mutant mice that lack the full adaptive response (deficient in both T and B cells) are resistant to dopaminergic death and behavioral deficiencies in this model. These mice are resensitized after reconstitution with WT splenocytes. To more directly provide evidence for humoral/IgG involvement, we show that deficiency of Fcγ receptors, which are critical for activation of macrophages/microglia by binding to IgGs, is also protective in this protracted model. FcγR-deficient mice display improved behavior and impaired microglial activation. Interestingly, however, Rag2 mutant but not FcγR-deficient mice are resistant to a more standard N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine paradigm where death is more rapid. Taken together, these data indicate that, provided sufficient time, the humoral arm of the adaptive immune system can play a critical functional role in modulating the microglial response to dopaminergic degeneration and suggest that this humoral component may participate in degeneration in Parkinson's disease.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190686

DOI: 10.1074/jbc.M111.244830
PubMed: 21693708
PubMed Central: 3190686

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Involvement of the Fcγ Receptor in a Chronic <italic>N</italic>
-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss<xref ref-type="fn" rid="FN1">*</xref>
</title>
<author><name sortKey="Lira, Arman" sort="Lira, Arman" uniqKey="Lira A" first="Arman" last="Lira">Arman Lira</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kulczycki, Jerzy" sort="Kulczycki, Jerzy" uniqKey="Kulczycki J" first="Jerzy" last="Kulczycki">Jerzy Kulczycki</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Slack, Ruth" sort="Slack, Ruth" uniqKey="Slack R" first="Ruth" last="Slack">Ruth Slack</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Anisman, Hymie" sort="Anisman, Hymie" uniqKey="Anisman H" first="Hymie" last="Anisman">Hymie Anisman</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Park, David S" sort="Park, David S" uniqKey="Park D" first="David S." last="Park">David S. Park</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21693708</idno>
<idno type="pmc">3190686</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190686</idno>
<idno type="RBID">PMC:3190686</idno>
<idno type="doi">10.1074/jbc.M111.244830</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">000559</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000559</idno>
<idno type="wicri:Area/Pmc/Curation">000559</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000559</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000934</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000934</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000B86</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B86</idno>
<idno type="wicri:Area/PubMed/Curation">000B86</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B86</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B86</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B86</idno>
<idno type="wicri:Area/Ncbi/Merge">000F02</idno>
<idno type="wicri:Area/Ncbi/Curation">000F02</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000F02</idno>
<idno type="wicri:doubleKey">0021-9258:2011:Lira A:involvement:of:the</idno>
<idno type="wicri:Area/Main/Merge">001714</idno>
<idno type="wicri:Area/Main/Curation">001646</idno>
<idno type="wicri:Area/Main/Exploration">001646</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Involvement of the Fcγ Receptor in a Chronic <italic>N</italic>
-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss<xref ref-type="fn" rid="FN1">*</xref>
</title>
<author><name sortKey="Lira, Arman" sort="Lira, Arman" uniqKey="Lira A" first="Arman" last="Lira">Arman Lira</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kulczycki, Jerzy" sort="Kulczycki, Jerzy" uniqKey="Kulczycki J" first="Jerzy" last="Kulczycki">Jerzy Kulczycki</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Slack, Ruth" sort="Slack, Ruth" uniqKey="Slack R" first="Ruth" last="Slack">Ruth Slack</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Anisman, Hymie" sort="Anisman, Hymie" uniqKey="Anisman H" first="Hymie" last="Anisman">Hymie Anisman</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Park, David S" sort="Park, David S" uniqKey="Park D" first="David S." last="Park">David S. Park</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of Biological Chemistry</title>
<idno type="ISSN">0021-9258</idno>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term>
<term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology)</term>
<term>Animals</term>
<term>Cell Death (drug effects)</term>
<term>Cell Death (genetics)</term>
<term>Cell Death (immunology)</term>
<term>DNA-Binding Proteins (genetics)</term>
<term>DNA-Binding Proteins (immunology)</term>
<term>DNA-Binding Proteins (metabolism)</term>
<term>Disease Models, Animal</term>
<term>Immunoglobulin G (genetics)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Immunoglobulin G (metabolism)</term>
<term>MPTP Poisoning (genetics)</term>
<term>MPTP Poisoning (immunology)</term>
<term>MPTP Poisoning (metabolism)</term>
<term>Mice</term>
<term>Mice, Knockout</term>
<term>Neurotoxins (adverse effects)</term>
<term>Neurotoxins (pharmacology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (genetics)</term>
<term>Parkinson Disease, Secondary (immunology)</term>
<term>Receptors, IgG (genetics)</term>
<term>Receptors, IgG (immunology)</term>
<term>Receptors, IgG (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA-Binding Proteins</term>
<term>Immunoglobulin G</term>
<term>Receptors, IgG</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>DNA-Binding Proteins</term>
<term>Immunoglobulin G</term>
<term>Receptors, IgG</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA-Binding Proteins</term>
<term>Immunoglobulin G</term>
<term>Receptors, IgG</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Death</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Cell Death</term>
<term>MPTP Poisoning</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cell Death</term>
<term>MPTP Poisoning</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Mice</term>
<term>Mice, Knockout</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Although there is growing evidence for a role of the innate immune response in Parkinson's disease, the nature of any humoral response in dopaminergic degeneration is uncertain. Here we report on a protracted N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of dopaminergic death that potentially allows a more full adaptive humoral response to develop. Rag2 mutant mice that lack the full adaptive response (deficient in both T and B cells) are resistant to dopaminergic death and behavioral deficiencies in this model. These mice are resensitized after reconstitution with WT splenocytes. To more directly provide evidence for humoral/IgG involvement, we show that deficiency of Fcγ receptors, which are critical for activation of macrophages/microglia by binding to IgGs, is also protective in this protracted model. FcγR-deficient mice display improved behavior and impaired microglial activation. Interestingly, however, Rag2 mutant but not FcγR-deficient mice are resistant to a more standard N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine paradigm where death is more rapid. Taken together, these data indicate that, provided sufficient time, the humoral arm of the adaptive immune system can play a critical functional role in modulating the microglial response to dopaminergic degeneration and suggest that this humoral component may participate in degeneration in Parkinson's disease.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Anisman, Hymie" sort="Anisman, Hymie" uniqKey="Anisman H" first="Hymie" last="Anisman">Hymie Anisman</name>
<name sortKey="Kulczycki, Jerzy" sort="Kulczycki, Jerzy" uniqKey="Kulczycki J" first="Jerzy" last="Kulczycki">Jerzy Kulczycki</name>
<name sortKey="Lira, Arman" sort="Lira, Arman" uniqKey="Lira A" first="Arman" last="Lira">Arman Lira</name>
<name sortKey="Park, David S" sort="Park, David S" uniqKey="Park D" first="David S." last="Park">David S. Park</name>
<name sortKey="Slack, Ruth" sort="Slack, Ruth" uniqKey="Slack R" first="Ruth" last="Slack">Ruth Slack</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001646 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001646 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3190686
   |texte=   Involvement of the Fcγ Receptor in a Chronic N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss*
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21693708" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Involvement of the Fcγ Receptor in a Chronic N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss*

Involvement of the Fcγ Receptor in a Chronic N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of Dopaminergic Loss*

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.